Price fixing case caps a terrible week for generics
Shares in generics firms tumble in the wake of a huge lawsuit in the US alleging industry-wide price fixing, signalling many more years of pain for this sector.
Lundbeck leaps into the Tourette’s pipeline
By taking out Abide Therapeutics, Lundbeck has bought one of very few clinical-stage Tourette’s syndrome candidates.
Faint hope for Alder as Teva bucks dismal migraine trend
Alder hopes soon to launch its migraine drug eptinezumab, and will nervously have been watching the first full quarter’s sales of three similarly acting drugs.
12 years on, Astra draws a line under Medimmune
The acquisition marked Astrazeneca’s formal embrace of biologicals. Today the Medimmune name was dropped.
Lilly hopes volume can make up for late migraine entry
In a constrained pricing environment a volume play could help sales of Lilly's Emgality as it takes on Amgen’s Aimovig and Teva’s Ajovy.
The list of shame no biopharma wants to join
An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
Topping 2018 drug approvals will be a tall order
Was 2018 as good as it gets for drug approvals, or is the pipeline so stellar that even a US government shutdown cannot stop biopharma?
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.